Supplementary Figures S1 - S7, Table 1 from Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage

Supplementary Figure S1. Systemic agonistic anti-CD40 induces liver toxicity. Supplementary Figure S2. Systemic administration of anti-CD40 agonist enhances liver inflammation in a model of hepatic metastases. Supplementary Figure S3. Agonistic CD40 antibody induces CD11b+ Gr-1+ cell maturation in the liver. Supplementary Figure S4. Representative gating of CD40 and CD80 expression on tumor-induced hepatic CD11b+ Gr-1+ cells after agonist CD40 antibody injection. Supplementary Figure S5. Differential contribution of G-MDSC and MDSC subsets in agonistic CD40 antibody-mediated liver damage. Supplementary Figure S6. Purity and phenotype of tumor-induced hepatic CD11b+enriched cells used for congenic transfer experiments. Supplementary Figure S7. Human anti-CD40 antibody modulates arginase expression in human MDSC. Supplementary Table 1. List of patients.